Human inhalable antibody fragments neutralizing {SARS}-{CoV}-2 variants for {COVID}-19 therapy
Articolo
Data di Pubblicazione:
2021
Citazione:
Human inhalable antibody fragments neutralizing {SARS}-{CoV}-2 variants for {COVID}-19 therapy / O. Minenkova, D. Santapaola, F. Maria Milazzo, A. Maria Anastasi, G. Battistuzzi, C. Chiapparino, A. Rosi, G. Gritti, G. Borleri, A. Rambaldi, C. Dental, C. Viollet, B. Pagano, L. Salvini, E. Marra, L. Luberto, A. Rossi, A. Riccio, E. Merlo Pich, M. Gabriella Santoro, R. De Santis. - (2021 Oct 15). [10.1101/2021.06.04.447066]
Abstract:
As of October 2021, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single chain variable fragment (scFv) antibodies (76clAbs) that block an epitope of the SARS-CoV-2 spike protein essential for ACE2-mediated entry into cells. 76clAbs neutralize the delta variant and other variants being monitored (VBMs) and inhibit spike-mediated pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. In two independent animal models, intranasal administration counteracted the infection. Due to high efficiency, remarkable stability, resilience to nebulization and low production cost, 76clAbs may become a relevant tool for rapid, self-administrable early intervention in SARS-CoV-2-infected subjects independently of their immune status.
Tipologia IRIS:
24 - Pre-print
Elenco autori:
O. Minenkova, D. Santapaola, F. Maria Milazzo, A. Maria Anastasi, G. Battistuzzi, C. Chiapparino, A. Rosi, G. Gritti, G. Borleri, A. Rambaldi, C. Dental, C. Viollet, B. Pagano, L. Salvini, E. Marra, L. Luberto, A. Rossi, A. Riccio, E. Merlo Pich, M. Gabriella Santoro, R. De Santis
Link alla scheda completa: